{"id":396957,"date":"2020-12-09T23:12:01","date_gmt":"2020-12-10T04:12:01","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=396957"},"modified":"2020-12-09T23:12:01","modified_gmt":"2020-12-10T04:12:01","slug":"stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\/","title":{"rendered":"Stellar Results from Kintor&#8217;s GT90001 and Opdivo Combo Therapy in the Second-line Treatment of Advanced Liver Cancer: ORR Reached up to 40%"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">SHANGHAI<\/span>, <span class=\"xn-chron\">Dec. 9, 2020<\/span> \/PRNewswire\/ &#8212; On December 9,\u00a02020, Kintor Pharmaceutical Limited (<span id=\"spanHghlte4b6\">HKEx: 9939)<\/span> is pleased to\u00a0announce that the Group has collected positive data in phase II clinical trials of combination therapy of ALK-1 (GT90001) antibody and PD-1 (Nivolumab or Opdivo) antibody for the second line therapy of advanced hepatocellular carcinoma (&#8220;HCC&#8221;) in <span class=\"xn-location\">Taiwan<\/span> (the &#8220;Phase II Clinical Trial&#8221;). The preliminary data of the ongoing Phase II Clinical Trial showed positive efficacy and safety results.\u00a0The data collected in the Phase II Clinical Trial will be released at the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) to be held between January 15-17,\u00a02021.<\/p>\n<ul type=\"disc\">\n<li>\n          <b>Poster presentation<\/b>\n        <\/li>\n<\/ul>\n<p>\n        <b>Abstract Title:\u00a0<br \/><\/b>Safety and efficacy of combination of GT90001, an anti-activin receptor-like kinase-1\u00a0(ALK-1) antibody, and nivolumab in patients with metastatic hepatocellular\u00a0carcinoma (HCC)<br \/><b>Abstract Number:\u00a0<\/b>326<br \/><b>First Author:<\/b>\u00a0Chiun Hsu, MD<\/p>\n<p>GT90001 is a fully humanised monoclonal antibody\u00a0that\u00a0inhibits ALK-1\/TGF-\u03b2 signal transduction and tumor angiogenesis and a potential first-in-class antibody for which we obtained an exclusive global license from Pfizer, Inc.\u00a0in <span class=\"xn-chron\">February 2018<\/span>. The Phase II Clinical Trial was commenced on <span class=\"xn-chron\">May 7, 2019<\/span> in <span class=\"xn-location\">Taiwan<\/span> to evaluate the safety and efficacy of GT90001 in combination therapy with Nivolumab in patients with advanced HCC who were\u00a0progressed on or intolerant to first line therapy with Sorafenib or Lenvatinib.<\/p>\n<p>The Phase II Clinical Trial (NCT03893695) was\u00a0a single-arm, open-ended\u00a0and two-stage clinical trial.\u00a0The Phase II\u00a0Clinical Trial mainly observed the safety, tolerability and anti-tumor activity of the combination therapy of GT90001 and Nivolumab. In the first stage (safety evaluation\u00a0cohort), six patients\u00a0were enrolled in the dose group of 7mg\/kg of\u00a0GT90001 biweekly and 3mg\/kg of Nivolumab biweekly. In the second stage (expanded cohort), 14 patients were enrolled at the same dose for combination therapy.\u00a0According to Response Evaluation Criteria in Solid Tumours (RECIST)\u00a0v1.1,\u00a0patients received treatment until experiencing disease progression or intolerable toxicity was developed. The primary efficacy endpoint was the objective response rate (ORR) assessed by the investigators.<\/p>\n<p>From July\u00a09,\u00a02019 to <span class=\"xn-chron\">September 30<\/span>, 2020,\u00a0among the 20 evaluable patients, eight patients (40.0%) were observed partial remission (PR). The side effects were well tolerated and manageable. The pharmacokinetic parameters of GT90001 and Nivolumab are similar to those of monotherapy.<\/p>\n<p>Dr. Tong Youzhi, the founder,\u00a0Chairman and CEO of Kintor Pharmaceutical, said, &#8220;Upon obtaining the exclusive global rights of GT90001, Kintor has\u00a0implemented\u00a0the development strategy to combine GT90001 with immunotherapy. GT90001, in combination with Nivolumab, has showed positive\u00a0efficacy and safety results.\u00a0We are actively initiating\u00a0MRCT phase II\/III clinical trials in <span class=\"xn-location\">China<\/span> and US for the treatment of advanced HCC. Meanwhile, we are exploring\u00a0innovative therapies\u00a0for the treatment of other solid tumors.&#8221;<\/p>\n<p>\n        <b>About GT90001<\/b>\n      <\/p>\n<p>GT90001 is a fully human monoclonal antibody against\u00a0ALK-1 (Activin Receptor-Like Kinase-1, Activin Receptor-Like Kinase-1). Kintor Pharmaceutical obtained the global exclusive development, production and commercialization rights from Pfizer in 2018. ALK-1 antibody can inhibit tumor blood vessel growth, reduce blood flow and angiogenesis by blocking the ALK-1 receptor pathway, thereby slowing tumor growth and changing the tumor microenvironment. As a potential first-in-class innovative drug in the world, it is expected to be used in the treatment of various solid tumors.Pfizer has conducted two phase I clinical trials on GT90001 in <span class=\"xn-location\">the United States<\/span>, <span class=\"xn-location\">Italy<\/span>, <span class=\"xn-location\">South Korea<\/span> and <span class=\"xn-location\">Japan<\/span>, which showed good safety and preliminary effectiveness in more than 100 patients with advanced solid tumors. Currently, Kintor Pharmaceutical is conducting phase II clinical trial of GT90001 combined with Nivolumab (PD-1 antibody) for the treatment of advanced liver cancer in <span class=\"xn-location\">Taiwan<\/span>.<\/p>\n<p>\n        <b>About Kintor Pharmaceutical Limited<\/b>\n      <\/p>\n<p>Founded in 2009, Kintor Pharmaceuticals aims to become a leading enterprise in the R&amp;D and commercialization\u00a0of &#8220;best-in-class&#8221; and &#8220;first-in-class&#8221; innovative therapies. The Company initially focused on\u00a0androgen receptor (AR) related diseases and researched and developed product portfolios in multiple channels covering cancers with a globally high incidence and illnesses yet to meet their clinical requirements, such as prostate cancer, breast cancer, liver cancer and hair loss. Kintor Pharmaceuticals has prospectively developed a diversified product pipeline that includes small molecule innovative drugs, bio-innovative drugs and combination therapies, including 5 products that are undergoing clinically researched androgen receptor antagonists, ALK-1 monoclonal antibody, mTOR kinase inhibitors and Hedgehog inhibitors, as well as PD-L1\/TGF-\u03b2 dual-targeting antibody, AR-Degrader and c-Myc inhibitors that are undergoing preclinical research. Globally, the Company has more than 60 issued patents\u00a0or under review, many of which are listed as the &#8220;Major New Drugs Discovery&#8221; in National 12th and 13th Five-Year Plans. On <span class=\"xn-chron\">22 May 2020<\/span>, the Company was officially listed on the Hong Kong Stock Exchange with the stock ticker 9939.HK. Please visit <a target=\"_blank\" href=\"http:\/\/www.kintor.com.cn\/\" rel=\"nofollow noopener noreferrer\">http:\/\/www.kintor.com.cn<\/a> for more information.<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN19626&amp;sd=2020-12-09\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40-301190036.html\">http:\/\/www.prnewswire.com\/news-releases\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40-301190036.html<\/a><\/p>\n<p>SOURCE  Kintor Pharmaceutical Limited<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=CN19626&amp;Transmission_Id=202012092308PR_NEWS_USPR_____CN19626&amp;DateId=20201209\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SHANGHAI, Dec. 9, 2020 \/PRNewswire\/ &#8212; On December 9,\u00a02020, Kintor Pharmaceutical Limited (HKEx: 9939) is pleased to\u00a0announce that the Group has collected positive data in phase II clinical trials of combination therapy of ALK-1 (GT90001) antibody and PD-1 (Nivolumab or Opdivo) antibody for the second line therapy of advanced hepatocellular carcinoma (&#8220;HCC&#8221;) in Taiwan (the &#8220;Phase II Clinical Trial&#8221;). The preliminary data of the ongoing Phase II Clinical Trial showed positive efficacy and safety results.\u00a0The data collected in the Phase II Clinical Trial will be released at the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) to be held between January 15-17,\u00a02021. Poster presentation Abstract Title:\u00a0Safety and efficacy of combination of GT90001, an anti-activin receptor-like kinase-1\u00a0(ALK-1) &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Stellar Results from Kintor&#8217;s GT90001 and Opdivo Combo Therapy in the Second-line Treatment of Advanced Liver Cancer: ORR Reached up to 40%&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-396957","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Stellar Results from Kintor&#039;s GT90001 and Opdivo Combo Therapy in the Second-line Treatment of Advanced Liver Cancer: ORR Reached up to 40% - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Stellar Results from Kintor&#039;s GT90001 and Opdivo Combo Therapy in the Second-line Treatment of Advanced Liver Cancer: ORR Reached up to 40% - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SHANGHAI, Dec. 9, 2020 \/PRNewswire\/ &#8212; On December 9,\u00a02020, Kintor Pharmaceutical Limited (HKEx: 9939) is pleased to\u00a0announce that the Group has collected positive data in phase II clinical trials of combination therapy of ALK-1 (GT90001) antibody and PD-1 (Nivolumab or Opdivo) antibody for the second line therapy of advanced hepatocellular carcinoma (&#8220;HCC&#8221;) in Taiwan (the &#8220;Phase II Clinical Trial&#8221;). The preliminary data of the ongoing Phase II Clinical Trial showed positive efficacy and safety results.\u00a0The data collected in the Phase II Clinical Trial will be released at the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) to be held between January 15-17,\u00a02021. Poster presentation Abstract Title:\u00a0Safety and efficacy of combination of GT90001, an anti-activin receptor-like kinase-1\u00a0(ALK-1) &hellip; Continue reading &quot;Stellar Results from Kintor&#8217;s GT90001 and Opdivo Combo Therapy in the Second-line Treatment of Advanced Liver Cancer: ORR Reached up to 40%&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-10T04:12:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN19626&amp;sd=2020-12-09\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Stellar Results from Kintor&#8217;s GT90001 and Opdivo Combo Therapy in the Second-line Treatment of Advanced Liver Cancer: ORR Reached up to 40%\",\"datePublished\":\"2020-12-10T04:12:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\\\/\"},\"wordCount\":800,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CN19626&amp;sd=2020-12-09\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\\\/\",\"name\":\"Stellar Results from Kintor's GT90001 and Opdivo Combo Therapy in the Second-line Treatment of Advanced Liver Cancer: ORR Reached up to 40% - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CN19626&amp;sd=2020-12-09\",\"datePublished\":\"2020-12-10T04:12:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CN19626&amp;sd=2020-12-09\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CN19626&amp;sd=2020-12-09\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Stellar Results from Kintor&#8217;s GT90001 and Opdivo Combo Therapy in the Second-line Treatment of Advanced Liver Cancer: ORR Reached up to 40%\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Stellar Results from Kintor's GT90001 and Opdivo Combo Therapy in the Second-line Treatment of Advanced Liver Cancer: ORR Reached up to 40% - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\/","og_locale":"en_US","og_type":"article","og_title":"Stellar Results from Kintor's GT90001 and Opdivo Combo Therapy in the Second-line Treatment of Advanced Liver Cancer: ORR Reached up to 40% - Market Newsdesk","og_description":"PR Newswire SHANGHAI, Dec. 9, 2020 \/PRNewswire\/ &#8212; On December 9,\u00a02020, Kintor Pharmaceutical Limited (HKEx: 9939) is pleased to\u00a0announce that the Group has collected positive data in phase II clinical trials of combination therapy of ALK-1 (GT90001) antibody and PD-1 (Nivolumab or Opdivo) antibody for the second line therapy of advanced hepatocellular carcinoma (&#8220;HCC&#8221;) in Taiwan (the &#8220;Phase II Clinical Trial&#8221;). The preliminary data of the ongoing Phase II Clinical Trial showed positive efficacy and safety results.\u00a0The data collected in the Phase II Clinical Trial will be released at the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) to be held between January 15-17,\u00a02021. Poster presentation Abstract Title:\u00a0Safety and efficacy of combination of GT90001, an anti-activin receptor-like kinase-1\u00a0(ALK-1) &hellip; Continue reading \"Stellar Results from Kintor&#8217;s GT90001 and Opdivo Combo Therapy in the Second-line Treatment of Advanced Liver Cancer: ORR Reached up to 40%\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-10T04:12:01+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN19626&amp;sd=2020-12-09","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Stellar Results from Kintor&#8217;s GT90001 and Opdivo Combo Therapy in the Second-line Treatment of Advanced Liver Cancer: ORR Reached up to 40%","datePublished":"2020-12-10T04:12:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\/"},"wordCount":800,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN19626&amp;sd=2020-12-09","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\/","name":"Stellar Results from Kintor's GT90001 and Opdivo Combo Therapy in the Second-line Treatment of Advanced Liver Cancer: ORR Reached up to 40% - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN19626&amp;sd=2020-12-09","datePublished":"2020-12-10T04:12:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN19626&amp;sd=2020-12-09","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN19626&amp;sd=2020-12-09"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Stellar Results from Kintor&#8217;s GT90001 and Opdivo Combo Therapy in the Second-line Treatment of Advanced Liver Cancer: ORR Reached up to 40%"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/396957","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=396957"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/396957\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=396957"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=396957"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=396957"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}